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INTRODUCTION
Breast cancer mortality rates are declining due to early detec-
tion and systemic adjuvant therapy. However, recurrence and 
distant metastasis, rather than a primary tumor, are the lead-
ing causes of death [1]. Although adjuvant treatment is indi-
vidualized according to the stage of cancer, nodal status, and 
hormonal status, not all patients show the same response to 
treatment. Knowledge of prognostic factors is important for 
predicting recurrence and metastasis and for choosing target 
therapies. Tumor size, axillary lymph node status, and histol- 
ogical grade have been established as markers for the clinical 
setting, and axillary lymph node status is the most influential 
predictor of recurrence and metastasis [2].
Known prognostic markers predict outcomes in 30% of pa-
tients; among the remaining 70%, 30% of patients will experi-
ence recurrence and metastasis. Accordingly, new markers are 
necessary for predicting the prognosis and for determining in-
dividualized treatment [1,2].
Lymphatic and blood vessel invasion to loco-regional lymph 
nodes or distant sites occur early in tumor metastasis. The 2005 
St. Gallen consensus guidelines suggested lymphovascular in-
vasion (LVI) as a predictor of postoperative prognosis [3]. This 
was confirmed in 2007, with some limitations [4]. However, 
LVI was defined using hematoxylin and eosin stained material 
(H&E stain), which cannot distinguish lymphatic invasion from 
blood vessel invasion [5]. Although there have been method-
ological problems distinguishing blood from lymphatic vessels, 
several specific markers have been discovered. Markers used 
to detect blood vessel invasion include elastic van Gieson stain, 
factor VIII-related antigen (vWF), CD34, CD31, and vascular 
endothelial growth factor receptor-3; and markers for lymphat-
ic invasion include podoplanin/D2-40, lymphatic vessel endo-
thelial hyaluronan receptor-1, laminin, type IV collagen, and 
homeobox prospero-like protein [6]. Among vascular mark-
ers, CD31 is a 130-kDa transmembrane glycoprotein platelet 
endothelial cell adhesion molecule-1 in the immunoglobulin 
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Purpose: Distant metastasis and recurrence are major prognostic 
factors associated with breast cancer. Both lymphovascular in-
vasion (LVI) and blood vessel invasion (BVI) are important routes 
for metastasis to regional lymph nodes and for systemic metas-
tasis. Despite the importance of vascular invasion as a prognos-
tic factor, application of vascular invasion as a histopathological 
criterion is controversial. The aim of this study was to distinguish 
LVI from BVI in prognosis and recurrence of breast cancer using 
an endothelial subtype specific immunohistochemical stain (podo-
planin, D2-40, and CD31). Methods: Sections from 80 paraffin-
embedded archival specimens of invasive breast cancer were 
stained for podoplanin, D2-40, or CD31 expression. Immunohis-
tochemical staining results were correlated with clinicopathologi-
cal features, such as tumor size, status of lymph node metastases, 
estrogen receptor status, progesterone receptor status, human 
epidermal growth factor receptor-2 expression, and recurrence. 
Patients with ductal carcinoma in situ and stage IV breast cancer 
were excluded. Results: A significant correlation was found between 
D2-40 LVI positivity and lymph node metastasis (p=0.022). We 
found a significant correlation between D2-40 LVI positivity and 
recurrence of breast cancer (p=0.014). However, no significant 
correlation was found between BVI and recurrence. A poorer dis-
ease free survival was shown for D2-40 positive LVI (p=0.003). In 
a multivariate analysis, the presence of D2-40 LVI positivity revealed 
a significant association with decreased disease-free survival. Con-
clusion: D2-40 LVI positivity was a more prognostic predictor of 
breast cancer than BVI.
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superfamily [6]. It is expressed on monocytes, platelets, select-
ed T-cell subsets, and endothelial cells and is found more com-
monly on blood vascular endothelial cells than lymphatic en-
dothelial cells [7]. In contrast, podoplanin is a 38-kDa integral 
transmembrane glycoprotein originally detected on the surface 
of renal glomerular podocytes in mice [8]. D2-40 is an IgG2a 
monoclonal antibody to the oncofetal M2A antigen, which is 
usually expressed in germ cell tumors and fetal testis [9]. Both 
D2-40 and podoplanin are widely used to distinguish lymphat-
ic from blood vessels, as they are expressed in lymphatic en-
dothelium [8,10], and D2-40 and podoplanin are now recog-
nized as one of the most specific and sensitive markers to de-
termine tumor cells in lymphatic vessels, which is known to be 
an important determinant of outcome [11]. However, despite 
the importance of blood vessel invasion as a prognostic factor, 
controversy still exists regarding the application of blood ves-
sel invasion (BVI) as a histopathological criterion. 
Therefore, the aim of this study was to distinguish between 
the role of LVI and BVI in the prognosis and recurrence of in-
vasive ductal breast cancer using an endothelial subtype specif-
ic immunohistochemical stain (podoplanin, D2-40, and CD31). 
METHODS
Patients
From January 2005 to February 2007, data from charts and 
pathological reports as well as tissues from consecutive patients 
with invasive ductal carcinoma of the breast at Korea Univer-
sity Anam Hospital were reviewed retrospectively. Patients with-
out surgical treatment, those diagnosed with ductal carcinoma 
in situ, metastasis, and those with insufficient follow up data, 
pathology slides, and tissue blocks were excluded. All patients 
gave written informed consent for the tumor evaluation. How-
ever, Institutional Review Board approval was not required at 
the time of the study, as the evaluation of the tumor was by im-
munohistochemistry. 
Of 80 patients, 41 underwent breast conserving surgery, and 
39 underwent a mastectomy; 43 patients underwent sentinel 
lymph node biopsy, and axillary lymph node dissection was 
performed according to the results. The remaining patients un-
derwent conventional axillary lymph node dissection. Patients 
received treatment with radiation, hormones, or chemothera-
py according to their pathological reports. The mean follow-
up period was 35±11.026 months.
The baseline characteristics of the patients are summarized 
in Table 1. Tumor size and nodal status were categorized ac-
cording to the TNM system criteria from the American Joint 
Committee on Cancer classification, and histological grade was 
evaluated using the Nottingham modification of the Bloom 
and Richardson histological grading criteria [12].
Immunohistochemistry 
Four paraffin-embedded tissue samples were cut into 4-µm 
thick sections. One section was routinely stained with H&E, 
whereas the others were stained with D2-40 (1:50; DakoCyto-
mation, Glostrup, Denmark), podoplanin (1:50; DakoCytoma-
Table 1. Patient characteristics
Characteristics No. of patients (%)
All patients   80 (100)
Age (yr)
   <50
   ≥50
 
   38 (47.5)
   42 (52.5)
Tumor size (T stage)
   1
   2
   3
   4
 
   41 (51.2)
   33 (41.3)
4 (5)
   2 (2.5)
Lymph node status
   0
   1-3
   4-9
   ≥10
 
   41 (51.3)
   18 (22.5)
     9 (11.2)
12 (15)
Histologic grade
   1
   2
   3
 
   15 (19.2)
   28 (35.9)
   35 (44.9)
Estrogen receptor status
   Positive
   Negative
 
   51 (63.7)
   29 (36.3)
Progesterone receptor status
   Positive
   Negative
 
   45 (56.3)
   35 (43.7)
HER2/neu expression
   Positive
   Negative
 
24 (30)
56 (70)
Ki-67 expression (%)
   <20
   ≥20
 
   17 (21.5)
   62 (78.5)
p53 
   Positive
   Negative
 
   37 (46.3)
   43 (53.7)
D2-40 LVI
   Positive
   Negative
 
  8 (10)
72 (90)
Podoplanin LVI
   Positive
   Negative
 
   7 (8.8)
   73 (91.2)
CD31 BVI
   Positive
   Negative
 
   18 (22.5)
   62 (77.5)
H&E LVI
   Positive
   Negative
 
   5 (6.2)
   75 (93.8)
Recur
   Yes
   No
  
     9 (11.3)
   71 (88.7)
LVI=lymphovascular invasion; BVI=blood vascular invasion; H&E=hae- 
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tion), or CD31 (1:40; DakoCytomation). Sections were depar- 
affinized in xylene and rehydrated in a graded series of etha-
nol to water. Peroxidase activity was inhibited by precipitation 
in methanol with 3% H2O2 for 5 minutes. Sections were cooked 
with citrate buffer (pH 6.0) in a pressure cooker at 12°C for 5 
minutes for antigen retrieval and incubated with the respective 
primary antibody at room temperature for 30 minutes. After 
washing, the sections were incubated with a secondary antibody 
(ChemMate Dako Envision; Dako) at room temperature for 
30 minutes. Subsequently, the sections were subjected to DAB 
(substrate buffer+DAB chromogen [×50]) for 5 minutes. The 
slides were counterstained with hematoxylin and then mounted. 
LVI was considered positive when tumor emboli were de-
tected in podoplanin, D2-40, and H&E positive vessels, and 
BVI was reported positive when tumor emboli were detected 
in CD31 positively stained vessels (Figure 1). Tumor emboli 
detected in the clear space without stained vessels was not con-
sidered positive for LVI and BVI in this study. 
Both estrogen (ER) and progesterone receptor (PR) status 
were assessed by standard immunohistochemical methods and 
were considered positive if the nuclear staining value was great-
er than 10%. Evaluations were performed by a single patholo-
gist using a light microscope. 
Results were correlated with clinicopathological features, such 
as tumor size, status of lymph node metastasis, hormonal re-
ceptor status, human epidermal growth factor receptor2 (HER2)/ 
neu expression, and recurrence. The relationship between LVI, 
BVI, and disease-free survival (DFS) was also analyzed.
Statistical analysis
The statistical analysis was conducted using SPSS version 
12.0 software (SPSS Inc., Chicago, USA). Correlations of clini-
copathological factors and recurrence with D2-40, podoplanin, 
CD31, and H&E staining were assessed using chi-square tests. 
To predict recurrence, logistic regression with a forward pro-
cedure was used for statistically significant factors in a multi-
variate analysis. Kaplan-Meier survival curves by the log-rank 
test were used for the univariate, and Cox-regression for mul-
tivariate analysis was performed to determine DFS. A p-value 
<0.05 was regarded as statistically significant. 
A B
C D
Figure 1. Tumor emboli in lymphatic vessel stained immunohistochemically with (A) D2-40, (B) podoplanin, (C) hematoxylin and eosin (H&E) stain, and 
tumor emboli in blood vessel stained with (D) CD31 (×400).D2-40 in Invasive Ductal Carcinomas of the Breast 107
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RESULTS
All patients were female, and ranged in age from 28 to 76 
years (mean, 49.4±10.727). LVI was detected by D2-40, podo-
planin and H&E stain in eight (10%), seven (8.8%), and five 
(5.2%) tumors, respectively. BVI was detected by CD31 stain 
in 18 tumors (22.5%). Among LVI detected cases, all podo-
planin and H&E stain cases were included in D2-40 stained 
cases. Seven tumors were positive for both D2-40 LVI and CD31 
BVI. 
Only one patient developed locoregional recurrence in the 
breast, and eight patients developed distant metastasis after sur-
gery. 
Correlation between D2-40, podoplanin, H&E stain LVI 
positivity, and clinicopathological factors
The relationship between D2-40, podoplanin LVI, and the 
clinicopathological factors is shown in Table 2. Recurrence was 
associated with positive LVI detected by D2-40 and H&E stain 
(p=0.014, p=0.037, respectively), but not by podoplanin stain 
(p=0.131). Tumors with D2-40 and podoplanin LVI were as-
sociated with a positive axillary lymph node (p=0.022, p= 
0.042, respectively), higher grade (p=0.022, p=0.045, respec-
tively), and negative ER (p=0.017, p=0.044, respectively). Vari-
ables significantly associated with H&E stain LVI positivity in-
cluded lymph node status (p=0.019), TNM stage (p=0.036), 
and ER status (p=0.037). 
Table 2. Correlation between D2-40, podoplanin, CD31, H&E stain, and clinicopathologic factors
Clinicopathological  
   factors
D2-40 LVI Podoplanin LVI CD31 BVI H&E LVI
Pos. (%) Neg. (%) p-value Pos. (%) Neg. (%) p-value Pos. (%) Neg. (%) p-value Pos. (%) Neg. (%) p-value
Age (yr)
   <50
   ≥50
 
1 (2.6)
7 (16.7)
 
37 (97.4)
35 (83.3)
0.038  
1 (2.6)
8 (14.3)
 
37 (97.4)
36 (85.7)
0.067  
8 (15.8)
12 (28.6)
 
32 (84.2)
30 (71.4)
0.174  
1 (2.6)
4 (9.5)
 
37 (97.4)
38 (90.5)
0.206
Tumor size (cm)
   ≤2
   >2
 
3 (7.3)
5 (12.8)
 
38 (92.7)
31 (87.2)
0.415  
3 (7.3)
4 (10.3)
 
38 (92.7)
35 (89.7)
0.644  
6 (14.6)
12 (30.8)
 
35 (85.4)
27 (69.2)
0.086  
1 (2.4)
4 (10.3)
 
40 (37.6)
35 (89.7)
0.151
No. of metastatic node
   0
   ≥1
 
1 (2.4)
7 (17.9)
 
40 (97.6)
32 (82.1)
0.022  
1 (2.4)
6 (15.4)
 
40 (97.6)
33 (84.6)
0.042  
7 (17.1)
11 (28.2)
 
34 (82.9)
28 (71.8)
0.236  
0 (0)
5 (12.8)
 
41 (100)
34 (87.2)
0.019
Stage
   1
   2
   3
 
1 (4)
3 (8.3)
4 (21.1)
 
24 (96)
33 (91.7)
15 (78.9)
0.071  
1 (4)
3 (8.3)
3 (15.8)
 
24 (96)
33 (91.7)
16 (84.2)
0.178  
3 (12)
9 (25)
6 (31.6)
 
22 (88)
27 (75)
13 (68.4)
0.117  
0 (0)
2 (5.6)
3 (15.8)
 
25 (100)
34 (94.4)
16 (84.2)
0.036
Histologic grade
   1
   2
   3
 
1 (6.7)
0 (0)
7 (20)
 
14 (93.3)
28 (100)
28 (80)
0.022  
1 (6.7)
0 (0)
6 (17.1)
 
14 (93.3)
28 (100)
29 (82.9)
0.045  
2 (13.3)
3 (10.7)
12 (34.3)
 
13 (86.7)
25 (89.3)
23 (65.7)
0.083  
0 (0)
0 (0)
5 (14.3)
 
15 (100)
28 (100)
30 (85.7)
0.034
Estrogen receptor  
   status
   Positive
   Negative
 
2 (3.9)
6 (20.7)
 
49 (96.1)
23 (79.3)
0.017
2 (3.9)
5 (17.2)
49 (96.1)
24 (82.8)
0.044
8 (15.7)
10 (34.5)
43 (84.3)
19 (65.5)
0.054
1 (2)
4 (13.8)
50 (98)
25 (85.2)
0.037
Progesterone  
   receptor status
   Positive
   Negative
 
3 (6.7)
5 (14.3)
 
42 (93.3)
30 (85.7)
0.263  
3 (6.7)
4 (11.4)
 
42 (93.3)
31 (88.6)
0.457  
8 (17.8)
10 (28.6)
 
37 (82.2)
25 (71.4)
0.254
 
2 (4.4)
3 (8.6)
 
43 (95.6)
32 (91.4)
0.452
HER2/neu expression
   Positive
   Negative
 
2 (8.3)
6 (10.7)
 
22 (91.7)
50 (89.3)
0.746  
2 (8.3)
5 (8.9)
 
22 (91.7)
51 (91.1)
0.932  
3 (12.5)
15 (26.8)
 
21 (87.5)
41 (73.2)
0.163  
2 (8.3)
3 (5.4)
 
22 (91.7)
53 (94.6)
0.617
Ki-67 expression (%)
   <20
   ≥20
 
1 (5.9)
6 (9.7)
 
16 (94.1)
56 (90.3)
0.628  
1 (5.9)
5 (8.1)
 
16 (94.1)
57 (91.9)
0.765  
4 (23.5)
13 (21)
 
13 (76.5)
49 (79) 
0.821  
0 (0)
4 (6.5)
 
17 (100)
58 (93.5)
0.286
p53
   Positive
   Negative
 
3 (8.1)
5 (11.6)
 
34 (91.9)
38 (88.4)
0.603  
3 (8.1)
4 (9.3)
 
34 (91.9)
39 (90.7)
0.851  
9 (24.3)
9 (20.9) 
 
28 (75.7)
34 (79.1)
0.719  
2 (5.4)
3 (7)
 
35 (94.6)
40 (93)
0.774
Recurrence
   Yes
   No
 
3 (33.3)
5 (7)
 
6 (66.7)
66 (93)
0.014  
2 (22.2)
5 (7)
 
7 (77.8)
66 (93)
0.131  
2 (22.2)
16 (22.5)
 
7 (77.8)
55 (77.5)
0.983  
2 (22.2)
3 (4.2)
 
7 (77.8)
68 (95.8)
0.037
LVI=lymphovascular invasion; BVI=blood vascular invasion; H&E=haematoxylin and eosin stain; Pos.=no. of positive cases; Neg.=no. of negative 
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Correlation between CD31 BVI positivity and 
clinicopathological factors
No correlation was found between CD31 BVI positivity and 
other clinicopathological factors such as age, tumor size, lymph 
node status, histological grade, hormonal status, or recurrence 
(Table 2).
Correlation between prognostic factors, LVI, BVI, and DFS
Univariate analysis using the Cox regression model demon-
strated the status of lymph node metastasis, HER2/neu expres-
sion, LVI status stained by D2-40 and H&E to be prognostic 
factors for DFS (Table 3). Among these factors, only negative 
Table 3. Univariate analysis of prognostic factors associated with dis-
ease-free survival in breast cancer patients
Prognostic factors   OR (95% CI) p-value
Age (<50 yr vs. ≥50 yr) 1.187 (0.319-4.422) 0.798
Tumor size (≤2 cm vs. >2 cm) 2.148 (0.537-8.593) 0.280
Nodal status (negative vs. positive)    3.826 (0.795-18.424) 0.047
Histologic grade (1&2 vs. 3)   4.436 (0.921-21.360) 0.063
ER status (negative vs. positive) 0.267 (0.067-1.066) 0.062
PR status (negative vs. positive) 0.207 (0.043-0.998) 0.050
HER2/neu expression (negative vs.
   positive)
  5.156 (1.289-20.623) 0.016
D2-40 LVI (negative vs. positive)   5.366 (1.337-21.527) 0.036
Podoplanin LVI (negative vs. 
   positive)
  3.356 (0.692-16.172) 0.131
CD31 BVI (negative vs. positive) 0.995 (0.207-4.792) 0.995
H&E LVI (negative vs. positive)   5.198 (1.077-25.099) 0.040
OR=odds ratio; CI=confidence interval; ER=estrogen receptor; PR= 
progesterone receptor; LVI=lymphovascular invasion; BVI=blood vas-
cular invasion; H&E=haematoxylin and eosin stain.
Table 4. Multivariate analysis of prognostic factors associated with dis-
ease-free survival in breast cancer patients
Prognostic factors   OR (95% CI) p-value
Nodal status (negative vs. positive)    2.332 (0.441-12.317) 0.319
HER2/neu expression (negative vs.
   positive)
  6.085 (1.500-24.690) 0.011
D2-40 LVI (negative vs. positive)   6.855 (1.683-27.922) 0.007
H&E LVI (negative vs. positive) 0.353 (0.024-5.248) 0.450
OR=odds ratio; CI=confidence interval; ER=estrogen receptor; PR= 
progesterone receptor; LVI=lymphovascular invasion; H&E=haematoxylin 
and eosin stain.
Figure 2. Comparison of disease-free survival between positive and negative lymphovascular invasion (LVI) stained by (A) D2-40, (B) podoplanin, (C) 
hematoxylin and eosin (H&E) stain, and blood vessel invasion stained by (D) CD31. 
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HER2/neu expression (odd ratio [OR], 6.085; p=0.011) and 
positive D2-40 LVI positivity (OR, 6.855; p=0.007) was sig-
nificantly related to poorer outcome on multivariate analysis 
(Table 4).
Patients with negative LVI D2-40 had better DFS than those 
with positive tumors (p=0.003), and similar results were shown 
for podoplanin and the LVI H&E stain (p=0.048, p=0.011, 
respectively) on Kaplan-Meier survival curve (Figure 2). How-
ever, no significance was found between positivity of BVI CD31 
and DFS (p=0.951). 
DISCUSSION
Because one of the main causes of cancer death is distant me-
tastasis, understanding the mechanism of tumor metastasis is 
important. Metastasis is often is explained by the metastatic 
cascade, in which the tumor cells first go through a process 
known as tumor cell dissociation in which they are separated 
from the primary tumor. They then invade the extracellular 
matrix, and enter the lymphatic or vascular system for trans-
port to distant organs in a process known as intravasation. Ex-
travasation occurs if tumor cells reach other organs where they 
can proliferate [1,13,14]. Based on this knowledge, if the exis-
tence of tumor cells in the lymphatic or vascular system can be 
predicted, the possibility of metastasis could also be predicted. 
As mentioned earlier, LVI was detected in the past using H&E 
stain in cases in which BVI could not be distinguished. How-
ever, new markers have been discovered along with advances 
in immunohistochemical technique. Using D2-40 as a marker, 
several studies have concluded that LVI is a prognostic factor, 
not only in breast cancer [15,16] but also in malignant mela-
noma, pulmonary adenocarcinoma, colorectal cancer, and gas-
tric cancer [17-21]. Rabban and Chen [22] questioned the spec-
ificity of D2-40 to detect lymphatic vessels and its use as a mark-
er to detect LVI without additional staining, as D2-40 is also 
expressed in myoepithelial cells which is a misinterpretation of 
true LVI from ductal carcinoma in situ (DCIS). However, their 
study showed that only few ducts with DCIS were D2-40 pos-
itive, and the entire circumference of the duct did not express 
D2-40. p63, or smooth muscle myosin immunostaining, which 
confirms the presence of myoepithelium, was only necessary 
for those patients with solid DCIS or in difficult cases that were 
morphologically confusing. Moreover, Arnaout-Alkarain et 
al. [23] proposed that D2-40 positivity in myoepithelial cells 
does not create a problem, as it is not difficult to distinguish 
from lymphatic channels. Usually ducts are much larger than 
vessels, and myoepithelium in smaller ducts is discontinuous, 
whereas endothelial lining is continuous in lymph vessels.
We used D2-40 and podoplanin as markers for LVI to deter-
mine its relationship with other clinicopathological factors and 
the prognosis. The LVI detection rate with D2-40 and podo-
planin was 10% and 8.8%, respectively, which was quite low 
compared with other reports, which were between 8.8% and 
86% [11,24]. In this study, we demonstrated that D2-40 stain 
could detect LVI the most and H&E stain the least. Moreover, 
despite the low detection rate, there was significant relationship 
between LVI and prognosis which also shows that LVI detec-
tion by D2-40 stain could be a significant marker for prognosis. 
Despite a short follow-up period, LVI-positive tumors stained 
with D2-40 and H&E indicated decreased DFS (p=0.008, 0.022, 
respectively), supporting results from other studies [15,17].
Tumor size is one of the strongest predictive factors for local 
recurrence, and tumors greater than 2 cm lead to decreased DFS 
[25]. In our study, there appeared to be more cases with tumor 
sizes greater than 2 cm in the D2-40 or podoplanin LVI posi-
tive group; however, no statistical significance was observed, 
which may be a result of the small study population. Although 
not as strong as tumor size and axillary lymph node status, tu-
mor grade is associated with prognosis, and higher grade tu-
mors show aggressive behaviors [2]. In our results, most LVI 
positive tumors were histological grade 3, which is consistent 
with other reports [17,26], and this can be explained by the 
speculation that aggressive tumors are more capable of invad-
ing lymphatic vessels. A significant relationship between LVI 
and ER status, with p-values of 0.017, 0.044, and 0.037 for D2-
40, podoplanin, and H&E stain, respectively, was also observed. 
Controversy exists regarding the prognostic value of hormone 
receptors, because overall survival and DFS are influenced by 
hormonal therapy for ER-positive tumors; however, ER-posi-
tive tumors tend to have more favorable characteristics, such as 
low-grade histology and a low proliferative index [2]. We sug-
gest that LVI negativity in ER-positive tumors provides prog-
nostic value.  
Axillary lymph node status is an important prognostic fac-
tor [2], and the metastatic route is through the lymphatic sys-
tem. Braun et al. [26] reported on the correlation between LVI 
and axillary lymph node metastasis, particularly in small (T1) 
tumors, in 247 cases using D2-40 as a marker. Similarly, Wong 
et al. [27] investigated the significance of LVI in node-negative 
tumors for predicting the necessity for radiation therapy or an 
axillary dissection. They concluded that LVI negative patients 
with small tumors have a low risk for lymph node metastasis 
and recommended that LVI positive patients undergo full ra-
diation therapy and/or axillary dissection. However, they did 
not mention the staining method used to detect LVI positivity. 
In our current study, LVI positivity stained with all three meth-
ods was correlated with lymph node status, supporting results 
from recent studies. Moreover, D2-40 LVI positivity and axil-110   Jung Ah Lee, et al.
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lary lymph node metastasis were associated with recurrence, 
although in the multivariate analysis, D2-40 LVI positivity was 
the only significant factor. 
BVI is an important factor associated with the hematogenous 
spread of tumor cells [1,13]. Unlike LVI studies, fewer studies 
have been conducted and less controversy exists regarding the 
prognostic significance of BVI [5,28,29]. Elastic van Gieson 
stain or vWF could be used to detect BVI; however, CD31 or 
CD34 has been preferred in some studies due to their specific-
ity [6]. BVI positivity ranged from 4.2% to 33% [29,30] in pre-
vious studies, and positivity was 22.5% when we used CD31 
as a marker for BVI. We found no significant relationship with 
other prognostic markers, and BVI was not associated with re-
currence or DFS. Kato et al. [30], who investigated BVI in Jap-
anese patients using elastic van Gieson stain and the VIII-re-
lated antigen, found a significant association between tumor 
size, lymph node status, histological grade, and survival. Lauria 
et al. [29] evaluated a large population consisting of 1,408 pa-
tients and reported that BVI was associated with a worse prog-
nosis and with lymph node metastasis; however, BVI was not 
significant in the multivariate analysis. But, LVI and BVI were 
distinguished with H&E stain, defining lymphatic vessels with 
a clear endothelial lining, blood vessels with a fibrin clot, and 
erythrocytes in the endothelial-lined space. Differences in re-
ports regarding BVI could be due to different staining methods.
The purpose of this study was to determine whether or not 
podoplanin, D2-40, or CD31 were significant prognostic fac-
tors. Not only are prognostic factors for breast cancer impor-
tant for predicting patient prognosis, but they might also be 
important with regard to treatment. Some patients could be 
over-treated with chemotherapy and suffer side effects, which 
could also lead to other serious conditions. If a patient’s risk for 
developing metastasis or recurrence could be accurately pre-
dicted, treatment could be individualized according to own 
his risk. Efforts should be made to determine the prognostic 
significance of LVI and BVI and to discover other prognostic 
factors. 
In summary, positive LVI detected by D2-40 was a predictor 
of prognosis and BVI did not have any significance. However 
further prospective studies with a larger population are neces-
sary to commonly use D2-40 stains as specific markers in clin-
ical settings. 
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